ReviewIndian journal of surgical oncology2025
Current Status of Immunotherapy in Resectable Lung Cancer.
Review in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the foremost cause of cancer-related mortality globally, with India accounting for a considerable share of the disease burden. Despite progress in surgical techniques and adjuvant therapies, outcomes for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) remain suboptimal, particularly in advanced stages. The introduction of immunotherapy has significantly altered the therapeutic landscape. While initially employed in metastatic and unresectable disease, immunotherapy is now gaining traction in the perioperative management of resectable NSCLC. Pivotal trials such as IMpower010, CheckMate 816, and KEYNOTE-091 have demonstrated meaningful improvements in outcomes, prompting a shift in treatment protocols. This evolution necessitates a broader scope of treatment through incorporation immunologic response assessment into operative planning, management of immune-related toxicities, and multidisciplinary coordination. Furthermore, emerging modalities including cancer vaccines, tumour-infiltrating lymphocyte therapy, and personalised immunotherapy strategies are pushing the boundaries of conventional surgical paradigms. This review critically examines current evidence supporting immunotherapy in lung cancer with particular emphasis on surgical implications. The integration of immunotherapy into surgical oncology represents a significant advancement, offering opportunities for improved outcomes while presenting new challenges in patient selection, timing, and multidisciplinary management. As India confronts a rising incidence of lung cancer, the role of immunotherapy with surgery holds promise for the future, transforming patient care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.